Cadila Healthcare bags US FDA nod for three drugs

Pharmaceutical firm, Cadila Healthcare on Monday said USFDA has given its nod it for the company's three products, taking the group's total number of approvals to 22.

The company would market all the three drugs -- Azathioprine Tablets, belonging to the immuno-suppressant segment, Divalproex Sodium Extended Release, an anti-convulsant and Venlafaxine Hydrochloride Tablets, an anti-depressant -- through its US subsidia ry Zydus Pharmaceuticals (USA) Inc.

The group received approvals to market Azathioprine Tablets of 50 mg, tentative approvals for Divalproex Sodium Extended Release Tablets of 250 and 500 mg and Venlafaxine Hydrochloride Tablets of 25, 37.5, 50, 75 and 100 mg, Cadila Healthcare informed BSE.

Read more at The Hindu Business Line

Zydus Cadila acquires Liva Healthcare

Zydus Cadila, a Ahmedabad based pharma company, has acquired majority stake in Liva Healthcare.

The Zydus group has picked up 97.5% stake in Liva Healthcare. The all cash transaction will be funded through cas accruals and debt, informs Zydus release. With the acquisition of Liva Healthcare, the company expects to establish its presence in the Rs 1500 crore derma segment which is the seventh largest therapeutic segment in the Indian pharma market.

Pankaj Patel, chairman & managing director, Zydus Cadila: "Our strategy over the last few years has also been to relentlessly focus and exploit opportunities for growth in the Indian pharma market". He further said that the acquisition unlocks great value for the group as it enables us to extend our expertise in a new therapy segment and cater to the needs of this segment. "We see this as a opportunity to fortify our presence in the Indian pharma market and lead by extending our reach", adds Patel.

Read more at Business Standard